Specialty EHR/IT

Group therapy documentation addiction treatment: Part 2 and the 2024 SAMHSA Final Rule

42 CFR Part 2, HIPAA, and the 2024 SAMHSA Final Rule in group session construction.

13 min read
October 21, 2026
Updated October 21, 2026
Group therapy documentation addiction treatment: Part 2 and the 2024 SAMHSA Final Rule
Quick answer
Group session documentation

Group therapy documentation in addiction treatment must satisfy two federal rules at once: 42 CFR Part 2 confidentiality for SUD records and HIPAA. The 2024 SAMHSA Final Rule aligned consent and breach notification with HIPAA but preserved Part 2’s core restriction on disclosing patient identity, meaning group note templates still require individualized notes that avoid naming other participants.

Addiction treatment programs that run group sessions operate under two federal confidentiality frameworks whose documentation requirements collide inside a single clinical note.

The 2024 SAMHSA Final Rule, published in the Federal Register on February 16, 2024 at 89 FR 12472 with a compliance date of February 16, 2026, modernized 42 CFR Part 2 by aligning its consent, breach notification, and patient rights framework with HIPAA. Group therapy documentation addiction treatment programs produce every day now sits inside that modernized framework, but the identity-disclosure rule that distinguishes Part 2 from HIPAA remains intact. An attendance roster, a case conceptualization that references another participant’s statements, and a note mentioning that someone else in the group also takes buprenorphine are all potential disclosures under 42 CFR §2.11.

Clinical directors and EHR administrators building SUD group note template libraries face a practical question: can a single shared note reference all participants, or does Part 2 require individualized notes with no cross-identification? The regulatory text, SAMHSA’s TIP 41 guidance on group counseling, and CMS billing rules for CPT 90853 converge on the second answer. The 2024 Final Rule did not create a loophole for roster-style documentation.

Consulting perspective on Group therapy documentation addiction treatment
The RealityThe template put every participant’s name in every participant’s note.
⚠️
The Problem
Generic templates violate Part 2 at the design layer
Generic behavioral health EHR templates ship with group note shells that auto-populate attendance into each participant’s note, creating a Part 2 disclosure of every co-participant’s SUD status every time any one patient’s chart is released.
🔧
The Solution
Modernization aligned HIPAA with Part 2 but kept the identity rule
The 2024 SAMHSA Final Rule modernized consent for treatment, payment, and health care operations, but left 42 CFR §2.11’s definition of patient identifying information unchanged. The cross-identification problem survives harmonization.
✅
The Resolution
Rebuild the group note template around separation
Attendance lives in a separate roster layer, each participant has an individualized note, and the EHR blocks cross-participant references at the data-entry layer rather than at release of information.

Why group therapy documentation addiction treatment carries two federal rulebooks

42 CFR Part 2 protects records of patients receiving diagnosis, treatment, or referral for substance use disorder from a federally assisted Part 2 program. HIPAA protects protected health information held by covered entities. For a Part 2 program that is also a HIPAA covered entity, both frameworks apply simultaneously to the same record. The 2024 SAMHSA Final Rule did not merge the two frameworks; it aligned them on specific points, consent for treatment, payment, and health care operations; breach notification; patient right to an accounting of disclosures, while preserving Part 2’s heightened protections against disclosures that would identify a person as a current or former SUD patient.

The identity-disclosure protection drives the group documentation issue. 42 CFR §2.11 defines patient identifying information to include any information that would identify a patient as having or having had a substance use disorder. A note in Patient A’s chart stating that Patient B shared about relapse triggers identifies Patient B as a SUD patient, inside Patient A’s record. Any downstream disclosure of Patient A’s chart to a billing contractor, an auditor, a non-Part 2 provider, now carries Patient B’s identifying information with it. That is a Part 2 disclosure by the program, and consent would be required from Patient B, not Patient A, before it occurs.

SAMHSA’s TIP 41, Substance Abuse Treatment: Group Therapy, addresses this directly in its chapters on confidentiality and group participation agreements. Participants sign agreements to maintain the confidentiality of other members. Programs apply the same discipline to their own clinical notes.

What the 2024 SAMHSA Final Rule changed for 42 CFR Part 2 documentation

The 2024 SAMHSA Final Rule, published at 89 FR 12472, permits a single patient consent for all future uses and disclosures of Part 2 records for treatment, payment, and health care operations, matching the HIPAA framework for TPO. It extends Part 2 to prohibit the use of records in civil, criminal, administrative, or legislative proceedings against the patient absent a court order. It applies HIPAA’s breach notification rule to Part 2 records. It gives patients the right to an accounting of disclosures and the right to request restrictions, consistent with HIPAA.

The compliance date of February 16, 2026 has passed. Programs operating in late 2026 are now operating under the harmonized rule. The practical effect for group documentation: a single, broad TPO consent now governs the ordinary flow of a patient’s own records to the program’s billing contractor, insurer, and treating clinicians. It does not govern disclosure of another patient’s identifying information embedded inside the first patient’s record. That disclosure still requires the second patient’s own written consent under 42 CFR §2.31 or a Part 2 permitted exception under 42 CFR §2.52 (research), 42 CFR §2.53 (audit and evaluation), or 42 CFR §2.63 (medical emergency).

Before and after the 2024 Final Rule
42 CFR Part 2 disclosure categories, consent required
Pre-rule and post-rule treatment of common disclosure categories. Yes equals written consent required.
Source: 42 CFR Part 2 (eCFR); SAMHSA 2024 Final Rule, 89 FR 12472, Confidentiality of Substance Use Disorder Patient Records. Compliance date 16 February 2026.

Confidentiality in group notes: what counts as a Part 2 disclosure

The threshold question for every entry in a group note is whether the entry, if read by someone outside the Part 2 program, would identify any patient as a SUD patient. Direct identifiers, names, initials paired with other data, dates of service paired with group identifiers, meet the threshold. Clinical content attributed to a named other participant meets the threshold. A roster of attendees reproduced inside a shared note meets the threshold.

Three documentation patterns reliably stay inside Part 2 confidentiality in group notes. First, each participant receives a separate note describing that participant’s engagement, response, and plan. Second, where another participant’s contribution shaped the session, the note describes the content without identifying the source, for example, a peer shared about recovery from benzodiazepine withdrawal, which the patient reported as supportive. Third, group identifiers are limited to session metadata (date, time, modality, duration, facilitator) stored separately from the clinical note or in a de-identified roster accessible only to the facilitator and billing.

SAMHSA’s guidance on substance use treatment treats the group setting as a context in which patients learn each other’s status by observation, which is not itself a Part 2 disclosure by the program. But a note created, stored, or transmitted by the program that identifies another participant is a disclosure by the program and triggers 42 CFR §2.13’s consent requirement.

A clinician in a quiet consulting space, note in hand
Compliance date 16 February 2026. The identity-disclosure rule survives harmonization.
Qventive Healthcare

Addiction treatment EHR template review

Qventive reviews addiction treatment EHR templates for 42 CFR Part 2 and HIPAA alignment, with a focus on group session construction, consent workflow, and billing documentation. The engagement produces a template inventory, a regulatory map, and a remediation plan sized to the program’s current EHR.

Building a compliant SUD group note template

A compliant SUD group note template separates three data layers. The individualized clinical note layer carries the patient’s name, diagnosis, treatment response, and plan, content that belongs in that patient’s chart and nowhere else. The session metadata layer carries the group identifier, date, time, modality (CPT 90853 or HCPCS H0005), duration, facilitator credentials, and participant count, content that supports billing and compliance review without identifying individuals. The attendance roster layer carries participant identifiers available to the facilitator and billing staff within the Part 2 program, and not reproduced inside individual notes.

TIP 41 and SAMHSA documentation standards for 42 CFR Part 2 programs converge on the same template logic. Each note stands alone and could be released, under its own patient’s §2.31 consent, without carrying another patient’s identifying information. Templates that auto-populate attendance lists into every participant’s note violate that principle at the design level. EHRs built for general behavioral health often ship with such templates; EHRs built for SUD treatment typically separate the roster from the note. EHR template development for a Part 2 program starts from the roster-separation principle rather than retrofitting it later.

Regulatory timeline
42 CFR Part 2 revision timeline for SUD documentation
Major federal revisions to the Part 2 confidentiality framework.
Sources: Federal Register; SAMHSA; 42 USC 290dd-2.

OUD medication group documentation under the opioid treatment program framework

Opioid treatment programs regulated under 42 CFR Part 8 operate under Part 2 confidentiality for all clinical records. OUD medication group documentation, medication management groups where methadone, buprenorphine, or naltrexone dosing is reviewed alongside counseling, carries the same cross-identification risk as any other group session. The note documents the individual patient’s dose, response, adherence, and plan. The group component, that other patients in the room are also receiving medication for opioid use disorder, is itself a Part 2 identifier for those others, and is not documented inside the patient’s note.

SAMHSA’s guidance on medications for substance use disorders treats medication-assisted treatment records as Part 2 records in full. The 2024 Final Rule’s TPO consent framework covers routine transmission of a patient’s own OUD medication records to their primary care provider, pharmacy, and insurer under a single signed consent. It does not authorize transmission of a co-participant’s OUD medication status captured incidentally in the first patient’s note. Addiction treatment practice management workflow design for OTPs reflects this split: individualized notes, shared metadata, protected roster.

CMS billing documentation for CPT 90853 and H0005

CMS billing requirements for CPT 90853 (group psychotherapy, other than of a multiple-family group) call for an individualized progress note for each participant per session. The CMS Internet-Only Manuals describe group psychotherapy as personal and group dynamics therapy delivered to multiple participants, with a per-participant documentation standard. State Medicaid programs billing HCPCS H0005 for alcohol and drug services group counseling apply equivalent per-participant note requirements, with state-specific duration thresholds (commonly 60 or 90 minutes) and credentialing additions.

The alignment with 42 CFR Part 2 is clean. Per-participant notes also solve the cross-identification problem: a note that stands alone for billing also stands alone for Part 2 confidentiality. Programs that merge participants into a single shared note save documentation minutes but create audit exposure on both the billing side (claim per participant without a per-participant note) and the confidentiality side (one note containing multiple patients’ identifying information).

EHR template considerations for Part 2 programs

Addiction treatment EHR template review focuses on four construction choices. First, group session scheduling populates a facilitator-visible roster that does not auto-write participant names into each attendee’s note. Second, the group note template is instantiated once per participant, with a shared session metadata header and a per-participant clinical body. Third, access controls limit roster visibility to the Part 2 program’s own staff, with no default routing of roster data to downstream HIPAA-only consumers. Fourth, the 2024 Final Rule’s single TPO consent is stored at the patient level and does not travel with another patient’s embedded identifier.

The practical test for any template is whether a release-of-information clerk, acting on a single patient’s valid §2.31 consent, can release that patient’s complete chart without the release containing a non-signing patient’s identifying information. If the answer requires manual redaction, the template is a Part 2 disclosure risk at the design layer. HIPAA and cybersecurity compliance reviews for Part 2 programs apply this test to every group note template before certifying the EHR configuration.

Group therapy documentation addiction treatment: frequently asked questions

What is 42 CFR Part 2 and how does it differ from HIPAA for group therapy documentation?
42 CFR Part 2 is the federal confidentiality regulation covering records of patients receiving diagnosis, treatment, or referral for substance use disorder from a federally assisted Part 2 program. HIPAA governs protected health information held by covered entities, including most healthcare providers. Programs subject to both apply both simultaneously; Part 2 adds heightened protections on top of HIPAA for the specific category of SUD identity. The 2024 SAMHSA Final Rule aligned Part 2’s consent, breach notification, and patient rights framework with HIPAA, but did not merge the two. For group therapy documentation, the practical difference is that HIPAA permits provider-to-provider sharing of a patient’s own records for treatment without specific consent, while Part 2 continues to require written consent before disclosing that someone is or was a SUD patient, including when that identity is embedded inside another patient’s group note.
Who can access a group therapy note under 42 CFR Part 2, and what consent is required?
Under 42 CFR Part 2, as modernized by the 2024 SAMHSA Final Rule, a patient’s own group therapy note can be disclosed to other Part 2 programs, HIPAA covered entities, and business associates for treatment, payment, and health care operations under a single written consent signed by that patient. The consent must comply with 42 CFR §2.31 content requirements, including the patient’s name, the recipient’s name or class of recipients, the purpose, the amount and kind of information, and the signature. HIPAA’s minimum necessary standard applies to the disclosure, and the HIPAA breach notification rule now applies to the record. However, a group note that embeds another participant’s identifying information cannot be released under the first patient’s consent alone, the second patient’s own 42 CFR §2.31 consent is required, or the disclosure must fit a §2.52 (research), §2.53 (audit), or §2.63 (medical emergency) exception. Programs that construct per-participant notes avoid the barrier at the template level.
Does the 2024 SAMHSA Final Rule allow EHRs to show other participants’ names in group notes?
No. The 2024 SAMHSA Final Rule, codified at 42 CFR Part 2 with a compliance date of February 16, 2026, modernized consent and breach notification but preserved 42 CFR §2.11’s definition of patient identifying information. Including another participant’s name, initials paired with other identifiers, or clinical content attributed to a named other participant in a patient’s group note creates a Part 2 disclosure of the other participant’s SUD status whenever that note is accessed outside the Part 2 program. The TPO consent framework introduced by the Final Rule covers the signing patient’s own records only. An EHR template that auto-populates attendance into every participant’s note violates Part 2 at the design layer, and the Final Rule does not change that result. Programs validating their EHR against the modernized rule should test the group note template specifically for cross-participant data leakage.
Can a group therapy note name other patients if the group is co-ed OUD medication management?
No. OUD medication management groups operate under 42 CFR Part 2 regardless of the specific medication involved, methadone under 42 CFR Part 8, buprenorphine under DEA scheduling and SAMHSA guidance, or naltrexone. The identifying information protected by 42 CFR §2.11 includes any information that would identify a person as receiving substance use disorder treatment, and medication-assisted treatment is squarely within that definition. A group note that names other participants discloses their OUD treatment status to anyone who later accesses that note under a different patient’s consent. The patient’s own medication dose, response, and adherence are documented in that patient’s note; references to co-participants are either anonymized or omitted. Programs operating opioid treatment programs under 42 CFR Part 8 apply the same discipline to counseling notes delivered alongside medication management.
What are the CMS billing documentation requirements for CPT 90853 in SUD treatment?
CMS requires an individualized progress note for each participant per group psychotherapy session billed under CPT 90853. The note must document the specific clinical issues addressed with that patient, the patient’s response, and the plan for continued treatment. The CMS Internet-Only Manuals treat group psychotherapy as personal and group dynamics therapy delivered to multiple participants, with a per-participant documentation standard rather than a single session summary. State Medicaid programs using HCPCS H0005 for alcohol and drug group counseling apply equivalent per-participant note requirements, with state-specific duration thresholds (commonly 60 or 90 minutes) and credentialing additions. The per-participant note standard aligns with 42 CFR Part 2’s identity-disclosure rule, so a single compliant note serves both billing and confidentiality requirements.
Is there a SAMHSA-published template for group therapy documentation?
SAMHSA’s Treatment Improvement Protocol 41, Substance Abuse Treatment: Group Therapy, discusses documentation principles for group counseling, including confidentiality agreements and record-keeping discipline, but does not publish a prescriptive note template. SAMHSA’s 42 CFR Part 2 guidance and FAQs cover disclosure rules rather than note construction. The National Institute on Drug Abuse publishes treatment approach materials that discuss documentation generally without a template. In practice, Part 2 aware EHR vendors build templates to the regulatory text and TIP 41 principles rather than to a SAMHSA-issued form. Programs validating a template typically map each field back to 42 CFR §2.11, 42 CFR §2.31, and CMS billing documentation requirements for CPT 90853 or HCPCS H0005.
What should an addiction treatment EHR template include to meet both Part 2 and HIPAA?
A compliant addiction treatment EHR template for group sessions separates three layers: a per-participant clinical note, session metadata available to billing and compliance, and an attendance roster restricted to facilitator and administrative access. The clinical note includes diagnosis, interventions, patient response, and plan, content attributable only to the signing patient. The session metadata includes CPT or HCPCS code, modifier, duration, facilitator credential, and site, with no participant names. The roster lives outside the individual notes and does not auto-populate into them. Access controls prevent downstream HIPAA-only recipients from receiving roster data, and the 42 CFR §2.31 consent on file governs each patient’s own records, not a co-participant’s identity embedded in them.
Ready when you are

Let’s meet

Qventive supports specialty and primary care practices across New Jersey. More than 30 years in healthcare IT, one team for EHR and infrastructure.

Sources
  1. 42 CFR Part 2, Confidentiality of Substance Use Disorder Patient Records (eCFR current version). ecfr.gov
  2. SAMHSA / HHS, Confidentiality of Substance Use Disorder Patient Records, Final Rule, 89 FR 12472 (Feb. 16, 2024). federalregister.gov
  3. SAMHSA, TIP 41: Substance Abuse Treatment: Group Therapy. library.samhsa.gov
  4. SAMHSA, Substance Use Treatment overview. samhsa.gov
  5. SAMHSA, Medications for Substance Use Disorders. samhsa.gov
  6. CMS, Internet-Only Manuals (Medicare Benefit Policy Manual, Pub. 100-02). cms.gov
  7. 42 CFR Part 8, Opioid Treatment Programs (eCFR current version). ecfr.gov
  8. National Institute on Drug Abuse, Treatment research topic. nida.nih.gov
  9. 42 USC §290dd-2, Confidentiality of records (statutory authority for Part 2). uscode.house.gov
Qventive Healthcare
Healthcare IT consulting and managed services, healthcare-exclusive since 1994. 200 Passaic Street, Hackensack, New Jersey. We serve as a business associate to the practices we support.